Our board of directors provide guidance as we pursue our mission of advancing promising medicines for neurologic disorders.

Vivek Ramaswamy

Vivek Ramaswamy has served on the board of Axovant since March 2015. He is the founder and Chief Executive Officer of Roivant Sciences. The Roivant family of companies includes multiple wholly-owned or majority-owned biopharmaceutical subsidiaries, each focused on a different disease area.

Prior to founding Roivant, Mr. Ramaswamy was an investor in the biotechnology sector. He currently serves as a member of the board of directors of Roivant Sciences and as chairman of the boards of directors of Axovant Sciences, Myovant Sciences, and Arbutus Biopharma Corporation.

Mr. Ramaswamy received his A.B. summa cum laude in biology from Harvard College and his J.D. from Yale Law School.

Roger Jeffs, PhD

Dr. Jeffs has served as a member of the board since February 2018. He has over 25 years of experience in the biopharmaceutical industry. He recently served as President and co-CEO of United Therapeutics, where he led the company through the approval of six rare disease products and managed the company’s development, regulatory, and commercial operations. Dr. Jeffs also served as a member of the company’s board of directors from 2001 to 2016.

Before joining United Therapeutics, he held positions in clinical development at Amgen and Burroughs Wellcome. He is currently an early-stage investor in the biopharmaceutical industry, and serves on the boards of directors of Albireo Pharma, Axsome Therapeutics, Dova Pharmaceuticals, and Sangamo Therapeutics.

Dr. Jeffs received his Ph.D. in pharmacology from the University of North Carolina School of Medicine and his B.A. in chemistry from Duke University.

George Bickerstaff

Mr. Bickerstaff has served as a member of our board since February 2018. He was Chief Financial Officer of Novartis Pharma AG from 2000 to 2005. Before joining Novartis, Mr. Bickerstaff served as CFO to several other companies and he has served on the boards of directors for multiple public companies in the healthcare industry including ARIAD Pharmaceuticals and Innoviva. Mr. Bickerstaff is currently a partner and the managing director of M.M. Dillon & Co., a healthcare and technology investment bank that he co-founded in 2005.

Mr. Bickerstaff received his B.S. in engineering and his B.A. in business administration from Rutgers University and he continued his executive education at Harvard Business School.

Atul Pande, MD

Dr. Pande has served as a member of the board since March 2015. He serves as Chief Medical Advisor of PureTech Health, President of Verity BioConsulting, a drug development consulting firm, and Chief Medical Officer of Tal Medical, a clinical-stage medical device company. From 2007 to April 2014, Dr. Pande was Senior Vice President and Senior Advisor, Pharmaceutical R&D, at GlaxoSmithKline. He has also held senior roles at Pfizer R&D, Parke-Davis/Warner-Lambert and Lilly Research Laboratories. Dr. Pande is also a non-executive board member of Autifony Therapeutics and  Karuna Pharmaceuticals.

Dr. Pande received an MBBS (Bachelor of Medicine, Bachelor of Surgery) from the University of Lucknow, India, and completed his research fellowship training in psychiatry at the University of Michigan Medical School and postgraduate specialty training and psychiatry residency program at Western University.

Berndt Modig

Mr. Modig has served as a member of the board since March 2015. He also serves as Chief Executive Officer of Pharvaris B.V. He served as Chief Financial Officer of Prosensa Holding N.V., a pharmaceutical company, from March 2010 until its acquisition by BioMarin Pharmaceutical Inc. in January 2015. From October 2003 to November 2008, Mr. Modig was Chief Financial Officer at Jerini AG where he directed private financing rounds, its initial public offering in 2005, and its acquisition by Shire plc in 2008. Before that, Mr. Modig served as Chief Financial Officer at Surplex AG from 2001 to 2003 and as Finance Director Europe of U.S.-based Hayward Industrial Products Inc. from 1999 to 2001. In previous positions, Mr. Modig was a Partner in the Brussels-based private equity firm Agra Industria from 1994 to 1999 and a Senior Manager in the Financial Services Industry Group of Price Waterhouse LLP in New York from 1991 to 1994. Mr. Modig currently serves as a director and member of the Audit Committee of Affimed N.V. – a publicly held pharmaceutical company. He also serves on the supervisory board of Kiadis Pharma N.V. and was a director of Mobile Loyalty plc from 2012 to 2013.

Mr. Modig received a bachelor’s degree in business administration, economics, and German from the University of Lund, Sweden, and an M.B.A. from INSEAD, Fontainebleau, France. He is a certified public accountant (inactive).

Ilan Oren

Ilan Oren has served as Vice President, Business Development at Dexcel Pharma Technologies Ltd., an international pharmaceutical company involved in the development, manufacture, and commercialization of pharmaceuticals, since September 2011. From 2007 to July 2011, he was employed by L.E.K. Consulting and advised clients in the life sciences sector on corporate strategy, mergers and acquisitions, licensing and drug commercialization projects. Mr. Oren currently serves as a director of Cynapsus Therapeutics Inc., a publicly traded specialty pharmaceutical company, and as a director of Roivant Sciences. Mr. Oren received his B.A. in Economics from Harvard College.